BMY · SLS 10-KMar 19 '26
“We provided GPS and Bristol-Myers Squibb provided nivolumab for this study.”
MRK · SLS 10-KMar 19 '26
“Given the potential immunobiologic and pharmacodynamic synergy between GPS and an immune check-point inhibitor (e.g., PD-1 inhibitor), we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab with exploratory long-term follow-up for OS and safety.”
BMY · CTMX 10-KMar 16 '26
“Pursuant to the BMS Agreement, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $50.0 million and estimated research and development service fees, and we were initially entitled to receive contingent payments of up to $25.0 million for additional targets and contingent payments for development, regulatory and sales milestones.”
MRK · CTMX 10-KMar 16 '26
“In the second quarter of 2024, CytomX announced a clinical collaboration with Merck to supply KEYTRUDA for evaluation of its combination with CX-801 in the Phase 1 study.”
BMY · AGEN 10-KMar 16 '26
“BMS received an exclusive worldwide license to develop, manufacture, and commercialize AGEN1777 and its derivatives.”
MRK · AGEN 10-KMar 16 '26
“Pursuant to our collaboration and license agreement with Merck, we exclusively licensed to Merck a monospecific antibody targeting ILT4 (MK-4830), which Merck advanced in a Phase 2 clinical trial.”
BMY · INTS 10-KMar 27 '26
“we entered into an agreement with BMS to evaluate the safety and efficacy of INT230-6 with Yervoy ® (ipilimumab), BMS's CTLA-4 immune checkpoint inhibitor, in patients with breast (17%), liver (5%), and advanced sarcoma cancer (78%).”
MRK · INTS 10-KMar 27 '26
“we entered into a supply agreement with Merck to evaluate the combination of INT230-6 with Keytruda ® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid malignancies, including pancreatic, bile duct, squamous cell and non-MSI high colon cancers.”